Thousands of women with breast cancer may be spared chemotherapy, thanks to landmark study co-authored by Massey physician-researcher
Seventy percent of women with the most common type of newly diagnosed breast cancer can now be identified and safely skip chemotherapy, according to the results of a landmark 12-year clinical research study.
A new study led by scientists at VCU Massey Cancer Center has shown that an experimental drug known as AZ32 selectively sensitizes brain tumors to radiation and significantly extends the survival of mouse models with human glioblastoma multiforme (GBM), the most common and deadly form of brain cancer.
Scientists at Virginia Commonwealth University believe they have uncovered an “Achilles heel” of glioblastoma multiforme (GBM), the most common and deadly form of brain cancer. Their study published this week in the Proceedings of the National Academy of Sciences details how a mechanism that protects glioma stem cells can potentially be exploited to develop new and more effective treatments for GBM.
VCU Massey Cancer Center is one of 17 global sites (and one of 14 in the U.S.) participating in a phase 2 clinical trial to evaluate the effectiveness and safety of an adoptive cell-transfer therapy to treat patients with metastatic melanoma. The trial, which uses the patient’s own tumor to grow immune cells designed to attack cancerous cells in the body, represents the first cell-based immunotherapy performed at VCU Massey Cancer Center.
Most healthy people barely notice infection with the human cytomegalovirus (hCMV), a form of the herpes virus that has evolved with humans over thousands of years and usually lays dormant in the body after initial infection. Now, in a study recently published in the journal PLOS ONE, a team of scientists from VCU Massey Cancer Center have shown a genetic relationship between the reactivation of hCMV and the onset of graft-versus-host disease (GVHD), a potentially deadly condition in which the immune system attacks healthy tissue following a bone marrow or stem cell transplant.